Small-cell lung cancer (SCLC) is an aggressive form of lung cancer that displays rapid proliferation and early metastatic potential. It accounts for approximately 15% of lung cancers and is strongly associated with tobacco carcinogens. Despite patients’ …
Context.—. Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice.Objective.—. To propose a standardized…
PURPOSEThe use of electronic patient-reported outcome measures (ePROMs) in supportive cancer care can lead to benefits, such as identifying at-risk patients in need of closer…
PURPOSEThe standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase…
PURPOSEYoung age is associated with increased risk of recurrence in hormone receptor (HR)–positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is…
This JAMA Insights discusses the need to fully assimilate evidence from observed and projected effects of climate change on health and invest in developing and…
Exciting Update: Rush to Crush Ca ncer has moved to a new fundraising platform for 2025! This means that if you previously participated in one…
PURPOSEConflicts of interest (COIs) in medical research can introduce biases affecting research integrity. This study investigated the scale and disclosure of COIs among Japanese authors…
PURPOSEHuman epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non–small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804) is…
Published in Leukemia & Lymphoma (Ahead of Print, 2025)
Myeloma Paper of the Day, March 10th, suggested by Robert Orlowski / BCMA-negative myeloma, cancer, CAR-T therapy, Guixiang Wang, Jiahuan Chen, Jianqing Mi,
